Leerink notes that Amgen’s (AMGN) Phase 2 MariTide showed “up to ~20% average weight loss at 52 weeks” in nondiabetic obese/overweight patients, which is roughly on par with the highest, 15 mg, dose of Eli Lilly’s (LLY) Zepbound at 52 weeks in the Phase 3 SURMOUNT-1 trial in nondiabetic obese/overweight patients. MariTide was said to be administered at “monthly or less frequent dosing.” The firm highlights that MariTide showed “no significant increases in free fatty acids,” whereas free fatty acids decreased by 7.5% with pooled groups of tirzepatide in the Phase 3 SURMOUNT-1 trial. Notably, the MariTide PR stated that “there was no association between the administration of MariTide and bone mineral density changes.” Leerink has a Market Perform rating on Amgen.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMGN:
- Morning Movers: Dick’s Sporting jumps and Kohl’s sinks following earnings
- Amgen down 4% after reporting MariTide weight loss study results
- Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
- Eli Lilly, others to buy after RFK-inspired drop, Barron’s says
- Amgen appoints Howard Chang as SVP of Research and Chief Scientific Officer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
